<DOC>
	<DOCNO>NCT02450331</DOCNO>
	<brief_summary>This Phase III , open-label , randomize , multicenter study evaluate efficacy safety adjuvant treatment atezolizumab compare observation participant muscle-invasive urothelial carcinoma ( UC ) high risk recurrence follow resection . Eligible participant randomize 1:1 ratio atezolizumab group control group .</brief_summary>
	<brief_title>A Study Atezolizumab Versus Observation Adjuvant Therapy Participants With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection IMvigor010</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm muscleinvasive UC ( also term transitional cell carcinoma [ TCC ] ) bladder upper urinary tract ( i.e. , renal pelvis ureter ) Participants receive prior platinumbased neoadjuvant chemotherapy , refuse ineligible ( `` unfit '' ) cisplatinbased adjuvant chemotherapy Representative formalinfixed paraffinembedded ( FFPE ) tumor specimens surgical resection ( i.e. , radical cystectomy , nephroureterectomy , lymph node dissection ) paraffin block ( block prefer ) least 15 unstained slide , associate pathology report , central test determine evaluable tumor PDL1 expression prior study enrollment Absence residual disease absence metastasis , confirm negative baseline compute tomography ( CT ) magnetic resonance imaging ( MRI ) scan pelvis , abdomen , chest 4 week prior randomization Full recovery cystectomy nephroureterectomy within 14 week follow surgery Eastern Cooperative Oncology Group ( ECOG ) performance status less equal ( &lt; /= ) 2 Life expectancy great equal ( &gt; /= ) 12 week Adequate hematologic endorgan function For woman postmenopausal surgically sterile : agreement remain abstinent use contraceptive method result failure rate le ( &lt; ) 1 percent ( % ) per year treatment period least 5 month last dose atezolizumab Any approve anticancer therapy within 3 week prior initiation study treatment Adjuvant chemotherapy radiation therapy UC follow surgical resection Treatment investigational agent participation another clinical trial therapeutic intent within 28 day five halflives drug prior enrollment Malignancies UC within 5 year prior Cycle 1 , Day 1 Pregnancy breastfeed Significant cardiovascular disease Severe infection within 4 week prior Cycle 1 , Day 1 Major surgical procedure diagnosis within 28 day prior Cycle 1 , Day 1 History severe allergic , anaphylactic , hypersensitivity reaction chimeric humanize antibody fusion protein Known hypersensitivity biopharmaceuticals produce Chinese hamster ovary cell component atezolizumab formulation History autoimmune disease Prior allogeneic stem cell solid organ transplant History idiopathic pulmonary fibrosis , organize pneumonia , druginduced pneumonitis , idiopathic pneumonitis , evidence active pneumonitis screen chest CT scan Positive test human immunodeficiency virus ( HIV ) and/or active hepatitis B hepatitis C tuberculosis Administration live , attenuate vaccine within 4 week Cycle 1 Day 1 Prior treatment cluster differentiation 137 ( CD137 ) agonists immune checkpoint blockade therapy , include antiCD40 , anticytotoxic Tlymphocyteassociated protein 4 ( antiCTLA4 ) , antiprogrammed death1 ( antiPD1 ) , antiprogrammed deathligand 1 ( antiPDL1 ) therapeutic antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>